Last updated on July 2019

Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin


Brief description of study

This is a study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme versus placebo in patients with malignant pleural mesothelioma with low argininosuccinate synthetase 1 expression. Malignant pleural mesothelioma have been found to require arginine, an amino acid. Thus the hypothesis is that by restricting arginine with ADI-PEG 20, the malignant pleural mesothelioma cells will starve and die.

Clinical Study Identifier: NCT02709512

Find a site near you

Start Over

Mayo Clinic

Phoenix, AZ United States
  Connect »

University of Chicago

Chicago, IL United States
  Connect »

Henry Ford Hospital

Detroit, MI United States
  Connect »

Mayo Clinic

Rochester, MN United States
  Connect »

MD Anderson Cancer Center

Houston, TX United States
  Connect »

Addenbrooke's Hospital

Cambridge, United Kingdom
  Connect »

Southampton General Hospital

Southampton, United Kingdom
  Connect »

Scunthorpe General Hospital

Scunthorpe, United Kingdom
  Connect »

Wansbeck General Hospital

Ashington, United Kingdom
  Connect »

Velindre Cancer Centre

Cardiff, United Kingdom
  Connect »

Edinburgh Cancer Centre

Edinburgh, United Kingdom
  Connect »

Austin Health

Heidelberg, Australia
  Connect »